<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675802</url>
  </required_header>
  <id_info>
    <org_study_id>Hysteroscopy</org_study_id>
    <nct_id>NCT03675802</nct_id>
  </id_info>
  <brief_title>Cervical Preparation in Hysteroscopy</brief_title>
  <official_title>Randomized Comparison of Vaginal Dinoprostone and Misoprostol for Cervical Ripening Before Diagnostic Hysteroscopy in Patients Who Have Undergone Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aljazeera Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aljazeera Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hysteroscopy was performed in the proliferativephase of the menstrual cycle.&#xD;
&#xD;
      The patients were given generalintravenous anesthesia (propofol/fentanyl) after the vulvar&#xD;
      and the vaginal area had been disinfected with a 7.5% Betadinesolution by the surgical nurse&#xD;
      All operations were performed by the same surgeon to avoid possible discrepancies between&#xD;
      different surgeons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Astandard rigid30 hysteroscope (Karl Storz bettocchi hysteroscope) with a 30° viewing&#xD;
      angleand an outer sheath diameter 5.5 mm, inner sheath diameter 4.3 mm and scope diameter 2.9&#xD;
      mmwas used in all procedures.&#xD;
&#xD;
      A speculum was introduced into the vagina, and the uterine cervixwas visualized. Initially,&#xD;
      the surgeon attempted to passthrough the cervical canal with the tool directly. When thatwas&#xD;
      not possible or when the cervical canal was too rigid ortoo tight, the cervix was grasped&#xD;
      with a tenaculum.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 23, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of women who will require cervical dilatation</measure>
    <time_frame>within an hour</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>GYN Disorders</condition>
  <arm_group>
    <arm_group_label>Arm number one ,misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm number 2 dinoprostone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <description>giving misoprostol to this group</description>
    <arm_group_label>Arm number one ,misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dinoprostone</intervention_name>
    <description>giving dinoprostine</description>
    <arm_group_label>Arm number 2 dinoprostone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients of reproductive age&#xD;
&#xD;
          2. have undergone a cesarean section at least once&#xD;
&#xD;
          3. an indication for diagnostic hysteroscopy for menstrualproblems or suspected&#xD;
             intrauterine lesions (suchas uterine polyps and ﬁlling defects in the uterine cavity)&#xD;
             by abnormal ﬁndings from hysterosalpingography,ultrasonography, or saline infusion&#xD;
             sonography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who delivered vaginally&#xD;
&#xD;
          2. Had undergone any other transcervical or transabdominal uterine and cervical&#xD;
             intervention other than cesareansection, such as loop electrosurgical procedures,&#xD;
             cervical cryotherapy, cervical biopsies, and spontaneousabortions, previous dilation,&#xD;
             and previous electiveabortions.&#xD;
&#xD;
          3. Patients with cervical pathology,e.g. tears or polyps.&#xD;
&#xD;
          4. The patients with a contraindicationto prostaglandins such as hypersensitivity,&#xD;
             bronchial asthma, glaucoma, severeasthma, cardiac, liver or kidney diseases.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women who needs diagnostic hysteroscopy</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mahmoud Alalfy, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud Alalfy</last_name>
    <phone>01002611058</phone>
    <email>mahmoudalalfy@ymail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Algazeerah</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Alalfy, master</last_name>
      <phone>+201002611058</phone>
      <email>mahmoudalalfy@ymail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ahmed Elgazzar, M.D</last_name>
      <phone>+201014005959</phone>
    </contact_backup>
    <investigator>
      <last_name>Mahmoud Alalfy, master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 16, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

